Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
GlobalData on MSN1d
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.
pharmaphorum5d
Multiple studies of Sarepta's DMD therapy halted after death
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...
Managed Healthcare Executive4d
Caregiver Burden and Value Assessments in Duchenne Muscular Dystrophy
Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...
BioSpace5d
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation
The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...
ET HealthWorld5d
Parents of muscular dystrophic patients protest in Delhi, demand access to high-cost treatment
One of the demands raised during the protests was access to 'Elevidys', a one-time gene therapy treatment that has the ...
Fierce Pharma4d
UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Sarepta, Roche seek to resume Elevidys trials
Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...
Morningstar4d
Sarepta Therapeutics Provides Update on ELEVIDYS
ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene ...